The reduction of tumor initiating activity and cell mediated mutagenicity of dimethylbenz[a]anthracene by a copper coordination compound.
Cu(II) (3,5-diisopropyl salicylate)2 (CuDIPS) which is an anti-inflammatory copper coordination compound (mol. wt. 503) possessing superoxide dismutase (SOD) activity was tested to determine its effect on 7,12-dimethylbenz[a]anthracene (DMBA)-induced initiation of tumors in mouse skin and on mutagenicity to 6-thioguanine resistance in a mouse keratinocyte mediated Chinese hamster V-79 cell system. A single application of CuDIPS (0.4 mg/mouse) administered at a short interval before DMBA application when followed by 20 weeks of promotion by TPA reduced the mouse skin tumor yield by 55%. When DMBA-induced cell-mediated mutagenesis was tested in the presence of CuDIPS a significant reduction in the number of V-79 6-thioguanine resistant mutants was observed.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000037:antagonists & inhibitors*; D000818:Animals; D001551:Benz(a)Anthracenes / Q000037:antagonists & inhibitors*; D001711:Biotransformation / Q000187:drug effects; D003043:Cocarcinogenesis; D006224:Cricetinae; D005260:Female; D051379:Mice; D012459:Salicylates / Q000494:pharmacology*; D012878:Skin Neoplasms / Q000139:chemically induced*
D001551:Benz(a)Anthracenes; D012459:Salicylates; C030865:copper bis(3,5-diisopropylsalicylate); D015127:9,10-Dimethyl-1,2-benzanthracene